RINA PATEL: Open Payments
NPI 1033664552 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,442 in 113 payments from 21 companies in 2025. Trend: 2023 $1,335 · 2024 $3,101 · 2025 $2,442
Food & beverage: $2,399Education: $43
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 19 | $382 |
| ABBVIE INC. | 22 | $298 |
| GENZYME CORPORATION | 8 | $237 |
| Janssen Biotech, Inc. | 8 | $172 |
| Lilly USA, LLC | 8 | $168 |
| Celltrion USA Inc. | 7 | $138 |
| Novo Nordisk Inc | 2 | $136 |
| Regeneron Healthcare Solutions, Inc. | 4 | $133 |
| QOL Medical, LLC | 5 | $131 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $124 |
Products named: DUPIXENT, XIFAXAN, TREMFYA, RINVOQ, OMVOH, VEGZELMA, Sucraid, NEFFY.
Industry payments across TX — which companies pay providers there.
